- Home
- Publications
- Publication Search
- Publication Details
Title
Predicting response to epigenetic therapy
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 1, Pages 47-55
Publisher
American Society for Clinical Investigation
Online
2014-01-01
DOI
10.1172/jci69737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
- (2015) Thomas Cluzeau et al. Oncotarget
- Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine
- (2013) María Abáigar et al. ANNALS OF HEMATOLOGY
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- (2013) Yun-Gyoo Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes
- (2013) C. Fili et al. CLINICAL CANCER RESEARCH
- Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- (2013) S. D. Gore et al. HAEMATOLOGICA
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)
- (2013) Cecile Bally et al. LEUKEMIA RESEARCH
- Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
- (2013) Lionel Adès et al. LEUKEMIA RESEARCH
- DNA methylation inhibitors in cancer: Recent and future approaches
- (2012) Christina Gros et al. BIOCHIMIE
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
- (2012) J. Aimiuwu et al. BLOOD
- Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort
- (2012) R. Itzykson et al. BLOOD
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
- (2012) P. Yan et al. BLOOD
- DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies
- (2012) Jacques Fahy et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
- (2012) A Mims et al. LEUKEMIA
- Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
- (2012) S Ettou et al. LEUKEMIA
- Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
- (2012) Massimo Breccia et al. LEUKEMIA & LYMPHOMA
- HDAC inhibitor-based therapies: Can we interpret the code?
- (2012) Maria New et al. Molecular Oncology
- Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine
- (2012) Vijaya L. Damaraju et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
- (2011) T. Braun et al. BLOOD
- MDS: Refining existing therapy through improved biologic insights
- (2011) Jordan Schecter et al. BLOOD REVIEWS
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
- (2011) Lieke H. van der Helm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
- (2011) Jane L. Hurwitz et al. EUROPEAN JOURNAL OF CANCER
- DNMT3B gene amplification predicts resistance to DNA demethylating drugs
- (2011) Laia Simó-Riudalbas et al. GENES CHROMOSOMES & CANCER
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- (2011) Omar Khan et al. IMMUNOLOGY AND CELL BIOLOGY
- Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment
- (2011) M Y Follo et al. LEUKEMIA
- Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine
- (2011) M T Voso et al. LEUKEMIA
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA
- (2010) Hui Yang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate
- (2010) Y. Hu et al. BLOOD
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression
- (2010) Rintaro Noro et al. CANCER SCIENCE
- Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
- (2010) M Y Follo et al. LEUKEMIA
- The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
- (2010) Maika Almstedt et al. LEUKEMIA RESEARCH
- Personalized Medicine: Marking a New Epoch in Cancer Patient Management
- (2010) M. Diamandis et al. MOLECULAR CANCER RESEARCH
- Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the Transcriptome
- (2010) Xiangning Qiu et al. PLoS One
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
- (2009) R. Garzon et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- (2009) P N Munster et al. BRITISH JOURNAL OF CANCER
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Biomarkers for predicting clinical responses to HDAC inhibitors
- (2009) Lindsay Stimson et al. CANCER LETTERS
- Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- (2009) P. Munster et al. CLINICAL CANCER RESEARCH
- PCR-Based Methods for the Enrichment of Minority Alleles and Mutations
- (2009) C. A. Milbury et al. CLINICAL CHEMISTRY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
- (2009) Lanlan Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating PTPN11 Mutants
- (2009) Z. Yang et al. MOLECULAR AND CELLULAR BIOLOGY
- Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation
- (2009) M. Rius et al. MOLECULAR CANCER THERAPEUTICS
- Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
- (2009) M. Y. Follo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
- (2008) V. R. Fantin et al. CANCER RESEARCH
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search